Prime Medicine, Inc. (PRME) Tops Q2 EPS by 2c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• Jefferies adds Uber to 'Franchise Picks' as bullish setup strengthens
• VASRO Research Highlights Ainos' Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset
• AMMO Inc. (POWW) Tops Q1 EPS by 3c